Co-Authors
This is a "connection" page, showing publications co-authored by Hualiang Jiang and Dao Wang.
Connection Strength
0.958
-
Effects of Shuanghuanglian oral liquids on patients with COVID-19: a randomized, open-label, parallel-controlled, multicenter clinical trial. Front Med. 2021 Oct; 15(5):704-717.
Score: 0.236
-
Beneficial effects exerted by hydroxychloroquine in treating COVID-19 patients via protecting multiple organs. Sci China Life Sci. 2021 02; 64(2):330-333.
Score: 0.224
-
Erratum to: Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. Sci China Life Sci. 2020 Oct; 63(10):1617-1618.
Score: 0.222
-
Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. Sci China Life Sci. 2020 10; 63(10):1515-1521.
Score: 0.221
-
Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients. Acta Pharmacol Sin. 2020 Sep; 41(9):1167-1177.
Score: 0.056